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Abstract. There is an increasing evidence that nutritional genomics 
represents a promise to improve public health. This goal will be 
reached by highlighting the mechanisms through which diet can reduce 
the risk of common polygenic diseases. Nutritional genomics applies 
high throughput functional genomic technologies and molecular tools 
in nutrition research, allowing a more precise and accurate knowledge 
of nutrient-genome interactions in both health and disease. 
Understanding the inter-relationships among genes, genes products, 
and dietary habits is fundamental to identify those who will benefit the 
most or be placed at risk by nutritional interventions. This chapter 
provides an overview of this novel nutritional approach, including the 
most relevant results of our recent research on the nutrigenomic effects 
of food polyphenols on cancer cells. Those studies would highlight the 
molecular mechanisms underlying the chemopreventive effects of 
those bioactive food compounds. 
 
Introduction 
 
 Until recently, nutrition research concentrated on nutrient deficiencies 
and   impairment  of          health.   The   importance  of   diet   to   sustain   health,  
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prevention and treatment of diseases has been known for a long time. The 
advent of genomics –high-throughput technologies for the generation, 
processing, and application of scientific information about the composition 
and functions of genomes – has created unprecedented opportunities for 
increasing our understanding of how nutrients modulate gene and protein 
expression influencing cellular and organismal metabolism and thus, 
ultimately impacting human health and well-being. Notably, the knowledge 
of the human genome has dramatically broadened the scope of studies in 
nutrition science [1-4].  
 Nutritional genomics is a relatively new and very fast-moving field of 
research and combines molecular biology, genetics, and nutrition [3, 5]. It 
provides a genetic understanding for how diet, nutrients or other food 
components affect the balance between health and disease by altering the 
expression and/or structure of an individual’s genetic makeup. The 
conceptual basis for this new branch of genomic research is built on the 
following premises [1,6]: 
 
• Diet and dietary components can alter the risk of disease 
development by modulating multiple processes involved with the 
onset, incidence, progression, and/or severity; 
• Diet and dietary components can act on the human genome, either 
directly or indirectly, to alter the expression of genes and gene 
products. 
• Diet and dietary components could potentially compensate for or 
accentuate effects of genetic polymorphisms. 
 
 The term nutritional genomics is frequently used as an umbrella term for 
two research specialties: nutrigenomics and nutrigenetics. However, it is 
important to note the difference between the terms nutrigenomics and 
nutrigenetics because although these terms are closely related they are not 
interchangeable. Nutrigenomics focuses on the effects of nutrients on genes, 
proteins, and metabolic processes, whereas nutrigenetics involves 
determining the effect of individual genetic variation on the interaction 
between diet and disease [2,7]. Thus, those working in nutrigenomics 
investigate the role of nutrients in gene expression, and those working in 
nutrigenetics determine how genetic polymorphisms (mutations) affect 
responses to nutrients [7,8]. Moreover, when reviewing scientific literature, 
other terms appear, such as epigenetics, transcriptomics, proteomics or 
metabolomics. All of them describe processes, new tools or situations of this 
emerging field of nutrition (Table 1). The key challenge is to determine 
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whether it is possible to utilize this information meaningfully to provide 
reliable and predictable personalized dietary recommendations for specific 
health outcomes. 
 Nutrigenetics and nutrigenomics hold much promise for providing 
better nutritional advice to the general public, genetic subgroups and 
individuals [11]. In the future, the integration of nutrition and genomics 
may lead to the enhanced use of personalized diets to prevent or delay the 
onset of disease and to optimize and maintain human health. The objectives 
of this chapter are to provide an overview of this novel nutritional 
approach. Moreover, we will also include the most relevant results of our 
research on the nutrigenomic effects of food polyphenols on cancer cells. In 
addition to the essential nutrients, such as calcium, zinc, selenium or 
vitamins, there are a variety of classes of nonessential nutrients and 
bioactive components, such as polyphenols, that seem to significantly 
influence health. Those bioactive components are known to modify a 
number of cellular processes associated with health and disease prevention, 
including carcinogen metabolism, hormonal balance, cell signaling, cell 
cycle control, apoptosis, and angiogenesis. Our studies are focused in 
highlighting the molecular mechanisms underlying the chemopreventive 
effects of those bioactive food compounds. 
 
Table 1. Definitions of terms used in nutritional genomics [9,10]. 
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1. Nutrigenetics 
 
 Nutrigenetics focuses on the effects that genetic variations have on 
the binomial diet/disease or on the nutritional requirements and 
recommended intakes for individuals and populations. To achieve its 
objectives, the methodology used in nutrigenetics includes the 
identification and characterization of genetic variants that are associated 
with, or are the responsible for a different response to certain nutrients or 
food components [6,11]. These variations generically designated as 
polymorphisms, including the polymorphisms of a single nucleotide 
(SNP, single-nucleotide polypmorphisms), differences in the number of 
copies, inserts, deletions, duplications and rearrangements or 
reorganizations. Undoubtedly, SNPs are the most frequent as they appear 
every 1,000 base pairs [12]. 
 These differences may determine the susceptibility of an individual to 
have a disease related to diet or to one or some diet components, as well as to 
influence in the individual’s response to diet changes. There is certain 
parallelism between nutrigenetics and phamacogenetics, although in the field 
of nutrition is more difficult to draw conclusions, since there are important 
differences between drugs and food components, such as chemical purity, 
number of therapeutic targets and duration of the exposure, among others    
[3, 9, 11]. 
 One of the best-described examples of the effect of SNPs is the 
relationship between folate and the gene encoding for MTHFR (5,10-
methylenetetrahydrofolate reductase) [13]. MTHFR has a role in supplying 5-
methylenetetrahydrofolate, which is necessary for the re-methylation of 
homocysteine to form methionine. Methionine is essential to many metabolic 
pathways including production of neurotransmitters and regulation of gene 
expression. Folate is essential to the efficient functioning of this MTHFR. 
There is a common polymorphism in the gene for MTHFR that leads to two 
forms of protein: the wild type (C), which functions normally, and the 
thermal-labile version (T), which has a significantly reduced activity. People 
with two copies of the wild-type gene (CC) or one copy of each (CT) appear 
to have normal folate metabolism. Those with two copies of the unstable 
version (TT) and low folate accumulate homocysteine and have less 
methionine, which increases their risk of vascular disease and premature 
cognitive decline [14]. 
 Thus, in people with low folic acid intake, higher serum homocysteine 
levels would be detected in TT homozygotes compared with other genotypes, 
which would lead them to an increased risk of cardiovascular disease (Figure 1). 
However, when the intake of folic acid in diet is higher, this increased 
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amount would compensate the DNA defect in people with the TT 
polymorphism, and homocysteine serum concentrations would not reach such 
high values and consequently not show hyperhomocysteinemia. According to 
this example of gene-diet interaction, a practical application for 
cardiovascular disease prevention would be to recommend a higher daily 
consumption of folic acid-rich food to those people with the TT genotype, 
since these individuals have higher folic acid requirements than the general 
population due to their genetic susceptibility. 
 
 
 
Figure 1. Gene-diet interaction. Folic acid intake may modulate the genetic risk of 
hyperhomocysteinemia conferred by the C677T polymorphism in the MTHFR gene. 
Hyperhomocysteinemia only would happen when the mutation occurs with a low 
folate intake [Adapted from 15]. 
 
 Another of the genes on which a very active research has been developed 
is the one that encodes for the synthesis of the lipoprotein APOA1 [16]. 
APOA1 is the main component of plasmatic HDL and seems to play an 
important role in the transport of cholesterol. It has been reported that a 
polymorphism in the gene promoter the -75 A/G (substitution of guanine by 
adenine), has an influence on the individual’s response to polyunsaturated 
fatty acids (PUFA) intake. Thus, women with the A/A genotype showed 
higher HDL-cholesterol levels in plasma after ingestion of PUFA, whereas 
those with genotypes A/G and G/G (wild type) did not show HDL-cholesterol 
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changes or even a certain decrease in response to the PUFA from diet 
(Figure 2). Therefore, for the individuals with the genotype A/A the ingestion 
of PUFA could be a good diet recommendation since it increases HDL. 
Those results illustrate the complexity of polymorphism-phenotype 
associations and underscore the importance of accounting for interactions 
between genes and environmental factors in population genetic studies. 
 The examples cited here and many others that can be found in the 
literature published until now [10,11,17-20] illustrate perfectly why 
nutrigenetics is also termed personalized nutrition, since its major goal is to 
identify and characterize genes, and nucleotide variants within these, that are 
associated (or account for) the differential responses to nutrients. In addition 
to providing a more rational basis for giving personalized dietary advice, the 
knowledge gained by applying genomic information to nutrition research will 
also improve the quality of evidence used for making population-based 
dietary recommendations. The sequencing of an individual’s genome has 
fueled interest in the field of personalized medicine [21,22], but replicating 
and validating nutrigenetic studies need to remain a priority before 
personalized nutrition can be considered a worthwhile approach to improve 
human health [23]. 
 
 
  
Figure 2. Effect of polyunsaturated fatty acid intake (>4%, 4-8% and >8% of energy) 
on high-density lipoprotein (HDL) cholesterol blood levels in women.  Means were 
adjusted for age, body mass index, alcohol consumption, tobacco smoking, and 
intakes of energy, saturated fatty acids, monounsaturated fatty acids, and PUFAs 
[Adapted from 16]. 
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2. Nutrigenomics 
 
 The term nutrigenomics was coined ten years ago to describe a branch of 
nutrition and food research that applies new profiling techniques for 
transcripts, proteins and metabolites to better understand the interplay of the 
genome with its nutritional environment. In this respect, nutrigenomics is still 
in its infancy and it will need time until it really delivers what was originally 
hoped [3,6,9].  
 The field of nutrigenomics harnesses multiple disciplines and includes 
dietary effects on genome stability (DNA damage at the molecular and 
chromosome level), epigenome alterations (DNA methylation), RNA and 
micro-RNA expression (transcriptomics), protein expression (proteomics) 
and metabolite changes (metabolomics), all of which can be studied 
independently or in an integrated manner [11, 24]. In this approach, nutrients, 
other food components, and even whole diets, are considered as “dietary 
signals” that are detected by “cellular sensors”. These sensors, that are part of 
cellular signaling cascades, can affect, in turn, all the processes involved in 
cell function. Therefore, they influence the transcription, translation and 
protein expression and different metabolic pathways, which ultimately form 
the phenotype [25, 26]. 
 Using the current genomic tools that include transcriptomics, proteomics 
and metabolomics, there are two approaches in nutrigenomic research. The 
first would identify genes, proteins or metabolites that are affected by the diet 
(nutrients or bioactive compounds) and determine which are the mechanisms 
involved in this interaction and, consequently, figure out the regulation 
pathways through which the diet induces these changes. In the second 
approach, early biomarkers are sought (genes, proteins or metabolites) that 
are linked with certain dietary compounds or to the whole diet [1,24]. Those 
biomarkers could act as a “warning signals” about changes in the homeostasis 
with could have implications for the health [10,11,24]. 
 There are numerous examples [9,11,27,28] that illustrate the interaction 
between food components and the genome, from mammalian cells in culture 
to human studies. However, most applications are still of descriptive nature. 
As an example of a typical nutrigenomic approach research, we will explain 
our research which its main goal is to study mechanisms underlying the 
potential chemopreventive effects of a certain type of well-known food 
compounds called polyphenols.  
 Polyphenols are the most abundant antioxidants in the diet. Their main 
dietary sources are fruits and plant-derived beverages such as fruit juices, tea, 
coffee, and red wine. Vegetables, cereals, cocoa, chocolate, and dry legumes 
also contribute to the total polyphenol intake. Their total dietary intake could 
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be as high as 1g/d, which is much higher than that of all other classes of 
phytochemicals and known dietary antioxidants [29]. Despite their wide 
distribution in plants, the health effects of dietary polyphenols have come to the 
attention of nutritionists only rather recently. Current evidence strongly 
supports a contribution of polyphenols to the prevention of cardiovascular 
diseases, cancers, and osteoporosis and suggests a role in the prevention of 
neurodegenerative diseases and diabetes mellitus [30]. However, our 
knowledge still appears too limited to formulate recommendations for the 
general population or for particular populations at risk of specific diseases.  
 For many years, polyphenols and other antioxidants were thought to 
protect cell constituents against oxidative damage through scavenging of free 
radicals. However, this concept now appears to be an oversimplified view of 
their mechanism of action [31,32]. More likely, cells respond to polyphenols 
mainly through direct interactions with receptors or enzymes involved in 
signal transduction, which may result in modification of the redox status of 
the cell and may trigger a series of redox-dependent reactions [33]. Both 
antioxidant and prooxidant effects of polyphenols have been described, with 
contrasting effects on the cell’s physiologic processes. As antioxidants, 
polyphenols may improve cell survival; as prooxidants, they may induce 
apoptosis and prevent tumor growth [30, 32]. However, the biological effects 
of polyphenols may extend well beyond the modulation of oxidative stress. 
One of the best-known examples involves the interaction of soy isoflavones 
with estrogen receptors and the effects of these compounds on endocrine 
function. These effects could explain the prevention by isoflavones of bone 
resorption among postmenopausal women [30]. A detailed understanding of 
the molecular events underlying these various biological effects is essential 
for the evaluation of the overall impact on disease risk and progression.  
 
2.1. Coffee polyphenols and breast cancer: A transcriptomics approach 
 
 Coffee is one of the most popular and widely consumed beverages 
throughout the world. Recent meta-analyses demonstrate inverse associations 
between coffee intake and the risk of colon, liver, breast and endometrial 
cancer [34-37]. In prospective population-based cohort studies, the inverse 
association between coffee consumption and risk of cancer has also been 
showed. The group of Naganuma et al. [38] found that the consumption of at 
least one cup of coffee per day was associated with a 49% lower risk of upper 
gastrointestinal cancer in a Japanese population, while Wilson et al. [39] 
found that men who regularly drink coffee appeared to have a lower risk of 
developing a lethal form of prostate cancer. The lower risk was evident when 
consuming either regular or decaffeinated coffee.  
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 It has been proposed that the inverse association between coffee intake 
and colon cancer could be explained, at least in part, by the presence of 
phenolic compounds in coffee [40]. Among the different phenolic 
compounds in coffee, the most abundant are hydroxycinnamic acids, which 
exist mainly in the esterified form. The best example is chlorogenic acid (5-
caffeoylquinic acid). In fact, coffee is the major source of chlorogenic acid in 
the human diet; the daily intake in coffee drinkers ranges from 0.5 to 1 g, 
whereas coffee abstainers will usually ingest <100 mg/day. Studies have 
showed that approximately the 33% of ingested chlorogenic acid and 95% of 
caffeic acid are absorbed intestinally [41]. Thus, about two-thirds of ingested 
chlorogenic acid reaches the colon where it is probably metabolized to caffeic 
acid [42]. Bioavailability data suggest that the biological effects of 
chlorogenic acid would become apparent after its metabolism to caffeic acid, 
and hence studying the effects of this acid is necessary. 
 As mentioned before, there is enough evidence from epidemiological 
data supporting the theory that coffee seems to reduce the risk of certain 
types of cancer; however, the molecular mechanisms underlying the 
chemopreventive effects of coffee remain unknown. Using a transcriptomics 
approach, the effect at the molecular level of the main phenolic compound in 
coffee, caffeic acid, at concentrations equivalent to one cup of coffee on 
human colon cancer cells (HT29) was studied. Furthermore, the effect of 
coffee polyphenols was also evaluated in breast cancer cells. 
 Colon adenocarcinoma HT29 cells were incubated with caffeic acid at a 
concentration equivalent to one cup of coffee for 24 hours. It was previously 
determined that this concentration did not cause any cytotoxic effect in the 
cell incubations. Then, gene expression was analysed by hybridization to the 
GeneChip Human Genome U133A plus 2.0 microarrays from Affymetrix, 
containing 47,000 transcripts and variants. Quantification was carried out 
with GeneSpring GX v.11.5.1 software (Agilent Technologies), which allows 
multi-filter comparisons using data from different experiments to perform the 
normalization, generation of lists and the functional classification of the 
differentially expressed genes. 
 A list of differentially expressed genes by 1.3-fold with a p-value cut-off 
of <0.05 was generated. Upon incubation with caffeic acid, 12 genes were 
overexpressed whereas 32 genes were underexpressed. Among the 
overexpressed genes, 33% belonged to the Transcription factors category, 
25% to Cell cycle, and 17% to Biosynthetic processes or Immune response. 
Within the underexpressed genes, again the category corresponding to Cell 
cycle was the most affected (30% of the genes) followed by Biosynthetic 
processes (15%) and Transcription factors (12%). Using these data, a 
Biological Association Network (BAN) was constructed using the Pathway 
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Analysis within the GeneSpring v.11.5.1, as described in Selga et al. [43]. 
Signal transducer and activator of transcription 5B (STAT5B) and Activating 
transcription factor 2 (ATF-2) appeared as highly interconnected nodes 
(Figure 3). In fact, STAT5B was overexpressed with respect to the control by 
33,4% in cells treated with caffeic acid, whereas ATF-2 was found 
underexpressed in HT29 incubated with caffeic acid (26% decrease compared 
to the control). 
 The changes in mRNA expression of these two main (STAT5B and 
ATF-2) nodes were confirmed by RT-PCR and at protein level by      
Western blot analysis   (Figure 4).     The key function of STAT5B is to  mediate  
  
 
 
Figure 3. Biological Association Network (BAN) of differentially expressed genes 
under caffeic treatment. The BAN was constructed with the Pathway Analysis 
software within GeneSpring v11.5.1. An expanded network was constructed by 
setting an advanced filter that included the categories of binding, expression, 
metabolism, promoter binding, protein modification and regulation. Only proteins are 
represented. The BAN shows the node genes STAT5B and ATF-2 that were further 
studied. 
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Figure 4. Quantification of mRNA and protein levels for STAT5B and ATF-2 in HT29 
cells. The mRNA levels of STATB5 (A) and ATF-2 (B) were determined in control 
HT29 cells (empty bars) and cells treated with caffeic acid (CA, filled bars) by RT-
Real Time. Results are expressed in fold-changes compared to the control, and are the 
mean + SE of 3 different experiments. *p<0.05 compared with the corresponding 
control. The protein levels of STAT5B (C) and ATF-2 (D) were determined in control 
HT29 cells (empty bars) and cells treated with caffeic acid (CA, filled bars) by 
Western blot. Blots were reprobed with an antibody against β-actin or tubulin to 
normalize the results. Results represent the mean ± SE of 3 different experiments. 
*p<0.05 and **p<0.01 compared with the corresponding control. 
 
the effects of the Growth Hormone, as STAT5B-null mice failed to respond 
effectively to this hormone [44]. Modulation of STAT5 levels or transcriptional 
activity has already been described in cells treated with natural compounds 
such as nobiletin, acitrus flavonoid [45] thea flavins [46] and silibinin, a natural 
polyphenolic flavonoid which is a major bioactive component of silymarin 
isolated from Silybum marianum [47]. Activation of STAT5A/B in human 
breast cancer has been shown to positively correlate with the differentiation 
status of the tumour. STAT5 have been also shown to transcriptionally regulate 
E2-sensitive proliferative genes such as cyclin D1 and c-Myc [48] suggesting 
that STAT5 may play a role in E2-stimulated breast cancer growth. STAT5 
activation has also been linked to regulating the expression of the cell cycle 
control protein cyclin D1 both directly and indirectly [48-50]. 
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 On the other hand, ATF-2 is a member of the ATF-cAMP response element-
binding protein (CREB) family of transcription factors that can bind to the cAMP 
response element (CRE) found in many mammalian gene promoters [51]. ATF-2 
exhibits both oncogenic and tumor suppressor functions [52)] CREs are found in 
several genes involved in the control of the cell cycle, e.g., the cyclin D1 gene 
and ATF-2 binding to this sequence stimulates the transcription of cyclin D1 
[53]. ATF-2 has been correlated with proliferation, invasion, migration, and 
resistance to DNA-damaging agents in breast cancer cell lines. 
 Therefore, the two main nodes identified in our work regulate cyclin D1 
transcription. Cyclin D1 is an important regulator of G1-S phase transition, 
and its expression in breast cancer cells is sensitive to estrogens and 
antiestrogens [54]. Cyclin D1 is over expressed at the mRNA and protein 
level in over 50% of the breast cancers either in the presence or absence of 
gene amplification and it is one of the most commonly over expressed 
proteins in breast cancer [55]. In order to know the influence that caffeic acid 
could have overcyclin D1 levels, since the expression of STATB5 and ATF-2 
is modified by this phenolic compound, cyclin D1 levels in MCF-7 cells were 
analyzed upon incubation with caffeic acid by Western Blot. As shown in 
Figure 5, incubation of MCF-7 cells with caffeic acid led to a drastic decrease 
in the levels of cyclin D1 protein, together with an increase in the levels of 
STAT5B, but there was no decrease in the levels of ATF-2.  
 
 
   
Figure 5. Expression of cyclin D1 upon incubation with caffeic acid in MCF-7 cells. 
The protein levels were determined in control MCF-7 cells (CNT) and in cells treated 
with caffeic acid (CA) by Western blot. Blots were reprobed with an antibody against β-
actin to normalize the results. Results represent the mean ± SE of 3 different 
experiments. *p<0.05 and ***p<0.001 compared with the corresponding control. 
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 It is believed that compounds that modulate cyclin D1 expression could 
have a role in the prevention and treatment of human neoplasia. For instance, 
flavopiridol, a synthetic flavonoid based on an extract from an Indian plant 
used for the potential treatment of cancer, induces a rapid decline in cyclin 
D1 steady-state protein levels [54]. Taking all these results together, 
inhibition of cyclin D1 expression appears to be a good approach for cancer 
treatment. In this direction our observation that coffee and caffeic acid are 
able to drastically reduce the expression of cyclin D1 in breast cancer cells 
could suggest that some coffee components could be used as a coadjuvant 
therapeutic tool in the treatment of breast cancer. 
 
2.2. Cocoa polyphenols and changes in the CYP1A1 gene expression 
 
 Cocoa is rich in polyphenols. In fact, cocoa has the highest flavanol 
contents of all foods on a per-weight basis and is a significant contributor to 
the total dietary intake of flavonoids [56]. The main subclasses of flavonoids 
found in cocoa are flavanols, particularly the flavanol monomers catechin and 
epicatechin, and their oligomers, also known as procyanidins [57]. Many 
examples of the health benefits of cocoa consumption can be found in the 
literature [58]. 
 Epidemiologic studies of cocoa intake and cancer risk are few, and those 
assessing overall mortality provide only weak support of the benefits of cocoa. 
However, human intervention trials indicate that cocoa favours intermediary 
factors in cancer progression—specifically, markers of antioxidant status 
[59]. Moreover, there is growing evidence that polyphenols may play a role 
in regulating apoptosis [60]. Apoptosis may be triggered intrinsically, 
through the mitochondrial pathway or extrinsically by death ligands and 
receptors. It is the external pathway that may potentially be modulated by 
bioactive food components. Flavanols found in cocoa have exhibited pro-
apoptotic effects. Proanthocyanadins inhibited growth of human lung cancer 
cells in vitro and in vivo [61], and epicatechin synergistically enhanced 
apoptosis in lung cancer cells treated with epigallocatechin-3-gallate (EGCG) 
[62]. Cocoa polyphenols have also been found to inhibit the mutagenic 
activity of heterocyclic amines in vitro and ex vivo [63]. 
 It has been reported that catechins from green tea could be effective in 
modulating estrogen-induced breast carcinogenesis, either interfering with 
receptor mediated pathways or reducing the production of genotoxic estrogen 
metabolites [64,65]. In our functional genomic study, we sought to evaluate 
the effect of cocoa flavonoids in a type of breast cancer cells (MCF-7), that 
are estrogen-receptor (ER)- dependent [66]. Estrogens are implicated in the 
initiation and promotion stages of breast cancer, and lifetime estrogen 
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exposure is a major risk factor for breast cancer [67]. Estrogens exert their 
carcinogenic effects by both estrogen receptor (ER)-dependent and 
independent mechanisms [68]. Most human breast cancers are initially 
positive for ER, and their growth can be stimulated by estrogens and 
inhibited by antiestrogens such as tamoxifen. 
 For that purpose, MCF-7 cells were incubated for 24h with a purified 
polyphenol cocoa extract (PCE). PCE was used as representative of the wide 
flavonoid spectrum (monomers and oligomers) present in cocoa and the 
concentrations used were not toxic. The differential gene expression analysis 
was done using PCR arrays. In particular, the expression profile of the 84 
genes included in the Stress & Toxicity PathwayFinderTM PCR Array was 
analyzed in MCF-7 cells both control and treated with a PCE. It was 
observed that the exposure to PCE decreased the expression of serpine 1 and 
up-regulated the expression of the CYP1A1, GADD45A, GDF15, GPX1, 
RAD23A, TP53, and XRCC2 genes (Table 2).  
 Among those genes, CYP1A1 was chosen for further validation since: (a) 
it was one of the most overexpressed gene upon incubation with PCE, (b) its 
overexpression in response to polyphenols had already been described, and 
(c) it plays an important role in the oxidative metabolism of estrogens. 
CYP1A1 is a candidate gene for low-penetrance breast cancer susceptibility 
because  it      plays  an  important      role  in  the        metabolism          of  xenobiotics  or 
carcinogens as well as in the oxidative metabolism of estrogens [2004]. 
CYP1A1 encodes  aryl  hydrocarbon       hydroxylase  (AHH)  which  catalyzes  a 
 
Table 2. List of under- and overexpressed genes in MCF-7 cells upon incubation with 
PCE for 24hours1. 
 
 
1The expression of each gene was reported as the fold change obtained after each 
treatment relative to control after normalization of the data. A cut-off of 2-fold was 
chosen since small changes in gene expression may represent important changes 
downstream those differentially expressed genes. Lists of differentially expressed 
genes, with a p-value<0.05, were generated from three independent experiments. 
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hydroxylation reaction in Phase I metabolism as a first step to increase the 
polarity of different molecules. Some of these metabolites can be more active 
than the initial molecules and behave as electrophilic compounds, thus 
initiating or promoting tumorigenic processes. Additionally, other metabolites 
may behave as chemoprotectors, such as the result of 2-hydroxylation in E1 
and E2 metabolism [70]. 
 Therefore, the differential expression of CYP1A1 mRNA in control 
versus treated cells was validated by RT- Real Time PCR (Figure 6A). Next, 
we investigated whether the changes at the RNA level were translated into 
protein. PCE treatment for 24 h led to a very modest increase in CYP1A1 
protein levels (1.2-fold). A time course incubation during 24, 48, 72 and 96 h 
led to an increase in CYP1A1 protein in MCF-7 cells of 3.9-fold after 48 h 
(Figure 6B). The difference between mRNA levels and the corresponding 
protein levels  may indicate that many of          the mRNA  molecules do not  reach  
 
      
 
Figure 6. CYP1A1 overexpression in MCF-7 cells treated with PCE. (A) Determination 
of CYP1A1 mRNA levels. Results are expressed in fold changes compared to MCF-7 
control and are the mean ± SE of 3 different experiments. (B) Determination of CYP1A1 
protein levels. Results represent the mean ± SE of 3 different experiments. Significant 
differences at all time points were evaluated by ANOVA plus post hoc Bonferroni 
comparison. (C) Determination of CYP1A1 activity in MCF-7 treated cells. Results are 
expressed relative to the activity of the control and represent the mean ± SE of 3 
different experiments. Significant differences at all time points were evaluated by 
ANOVA, plus post hoc Bonferroni comparison. 
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the translational machinery, probably because the translation mechanism is 
saturated in these conditions. Finally, CYP1A1 activity was determined upon 
incubation with PCE. An increase in CYP1A1 activity in good correlation 
with the observed increased in CYP1A1 protein levels was determined for 
both cell lines (Figure 6C). 
 The changes in CYP1A1 expression upon incubation with PCE could 
explain the antioxidant effect of flavonoids at the molecular level since this 
gene is involved in different oxidative pathways. Additionally, CYP1A1 
overexpression might interfere with estrogen metabolism and the production 
of estrogen metabolites in breast cells. The increase in CYP1A1 activity may 
shift estrogen metabolism toward the production of 2-OHE2 (2-
hydroxyoestradiol), a relatively non-genotoxic metabolite [71]. 
 Finally, we wanted to test whether cocoa polyphenols would exert a 
synergistic effect in combination with Tamofixen (TAM) since it has been 
previously described in breast cancer cells. Thus, MCF-7 cells were 
incubated with increasing concentrations of TAM (10-6–10-3M) either alone 
or in combination with PCE (250 ng/µL). Then, cell viability was determined 
after 48 h. The presence of PCE, which did not cause significant cell death by 
itself, increased the cytotoxic effect of TAM in MCF-7 cells (Figure 7).  
 
 
 
Figure 7. Effect of tamoxifen plus PCE on MCF-7 viability. Tamoxifen (TAM) either 
alone (filled squares) or in combination with PCE (250 ng/µL for 24H, empty circles). 
Results are expressed as % of living cells compared to the control only with DMSO 
(0.22%) and represent the mean ± SE of 3 different experiments. ***p<0.001. 
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 The reduction in cell viability reached an increase of 44% when combined 
with 10-6M TAM. Thus, in our conditions, the cytotoxic effect of TAM was 
enhanced by the combination with PCE in MCF-7 cells. The presence of PCE 
caused a synergistic effect, confirmed by the Chou-Talay method,  which led to a 
decrease in cell viability of up to 40% in MCF-7 cells at tamoxifen 
concentrations that did not affect cell viability by themselves. A plausible 
explanation of the synergistic effect observed could be that the increase in 
estrogen metabolism, induced by the PCE on CYP1A1, could lead to the 
reduction in the levels of estrogens in mammary tumours, thus contributing to the 
cytotoxic effect of tamoxifen. Nevertheless, further in vivo studies are necessary 
to analyse the synergism between tamoxifen and cocoa and to establish the 
possible benefits of cocoa polyphenol consumption during breast cancer therapy. 
 
3. Conclusions 
 
 Current global trends in food consumption may have an impact on 
disease progressions observed worldwide. The impact may occur because of 
gene regulation caused by nutrients, or by other unclear means that are yet to 
be discovered. The “omics” and associated technology will surely provide a 
greater understanding of the environmental and behavioral factors that 
influence phenotype and its relationship to health and wellness. It is highly 
likely that during the next decade the nutritional supplement and functional 
food industries will experience robust growth in response to advances in 
nutritional genomics research and its applications.  
 Parallel to this growth will be impressive progress in understanding the 
specific influence of certain food components on metabolic pathways and their 
role in health and disease. It will become increasingly less expensive to generate 
genetic information about individual persons, and such data are likely to redefine 
the current concept of preventive medicine. Moreover, through nutrigenomic 
research, new nutritional regulation of gene expression will hopefully come to 
light. If specific gene regulation by nutrients is identified in genes closely related 
to disease onset and progression, new arenas for disease prevention and potential 
for treatment will come to the foreground of nutrition and preventive medicine. 
Discoveries made in the field of nutrigenomics and nutrigenetics should translate 
into more effective dietary strategies to improve overall health by identifying 
unique targets for prevention. 
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